(Total Views: 84)
Posted On: 03/31/2022 9:50:49 AM
Post# of 74550

$CLVS News Article - Clovis Oncology's Rubraca (Rucaparib) Significantly Improves Progression-Free Survival in First-line Maintenance Treatment in Women with Ovarian Cancer Regardless of Their Biomarker Status in Phase 3 ATHENA-MONO Trial https://marketwirenews.com/news-releases/clov...04836.html


My Twitter: WhyteStocks